This is a preview of subscription content, log in via an institution to check access.
Notes
The analysis was conducted from the perspective of the UK NHS, and costs were reported in 2012 prices discounted at 3.5% per annum. Costs were those associated with drugs and healthcare resource use, including inpatient and outpatient care.
Reference
Willson J, et al. Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting beta-Agonists. Applied Health Economics and Health Policy : 29 Jun 2014. Available from: URL: http://doi.org/10.1007/s40258-014-0107-8
Rights and permissions
About this article
Cite this article
Tiotropium bromide worth it when added to usual asthma care. PharmacoEcon Outcomes News 707, 7 (2014). https://doi.org/10.1007/s40274-014-1394-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1394-x